Morgan Stanley analyst Steve Beuchaw maintained a Buy rating on Thermo Fisher (NYSE: TMO) today and set a price target of $254. The company’s shares closed yesterday at $239.97, close to its 52-week high of $249.95.
According to TipRanks.com, Beuchaw is a 4-star analyst with an average return of 12.6% and a 64.6% success rate. Beuchaw covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Myriad Genetics, and NanoString Tech.
Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $270.17, a 12.6% upside from current levels. In a report released yesterday, UBS also initiated coverage with a Buy rating on the stock with a $295 price target.
The company has a one-year high of $249.95 and a one-year low of $181.51. Currently, Thermo Fisher has an average volume of 1.32M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Services.